Tutorials › Bioavailability and Bioequivalence › Robust Population Bioequivalence Planning

Sample Size and Power · Tutorial 146 of 399

Robust Population Bioequivalence Planning

Learn to stress-test a population bioequivalence sample size across plausible variance models and choose a design whose power is not dependent on a single optimistic set of assumptions.

Advanced 12 min read

What You'll Learn

  • Define the population bioequivalence criterion and the planning power being stress-tested.
  • Separate uncertainty about variance components from departures in the random-effects model.
  • Use scenario-based simulation to assess sample-size sensitivity.
  • Distinguish minimum power across scenarios from probability-weighted assurance.
  • Quantify Monte Carlo error and identify warning signs in a fragile plan.

Why Robust Planning Matters

A population bioequivalence sample size is not a property of the target power alone. It also depends on the treatment mean difference, the variance components that determine the population variances, the covariance induced by the study design, and the inferential procedure used to assess the bioequivalence criterion. A calculation can meet its target under one set of assumptions and fall short if, for example, a variance component is larger than anticipated or the random-effects distribution is misspecified.

The goal of robust planning is not to find a sample size that guarantees success under every conceivable model. It is to make the assumptions explicit, examine a defensible range of alternatives, and determine whether the proposed sample size remains adequate across that range. The earlier material on Sample Size for Population Bioequivalence and Calculating Power for Population Bioequivalence supplies the basic planning framework; here the emphasis is sensitivity to its inputs and assumptions.

Definition: On the analysis scale specified by the protocol, let \(\mu_T\) and \(\mu_R\) be the population means for test and reference, and let \(\sigma_T^2\) and \(\sigma_R^2\) be their population variances. A common population bioequivalence criterion is $$ (\mu_T-\mu_R)^2+\sigma_T^2-\sigma_R^2 \leq \theta \sigma_R^2, $$ where \(\theta\) is the prespecified margin. The planning power at sample size \(n\) is the probability that the planned analysis concludes bioequivalence when the data are generated under specified true model parameters. Robust planning evaluates that power over a set of plausible parameter values and model assumptions.

The criterion combines a squared mean difference and a variance difference. Consequently, an assumption that affects either component can change the chance of meeting the criterion. The definition of \(n\), the margin, the analysis scale, the estimand, and the planned inferential procedure must all be fixed before comparing scenarios. In a crossover design, for instance, the number of evaluable subjects and the allocation across sequences should be defined consistently with the design.

For a simple illustration of the random-effects structure, suppose a response from subject \(i\) on formulation \(j\) is represented as \(Y_{ij}=\mu_j+b_i+u_{ij}+\epsilon_{ij}\). Here \(b_i\) is a subject effect common to formulations, \(u_{ij}\) is a subject-by-formulation effect, and \(\epsilon_{ij}\) is residual variation. If these components are independent with mean zero, the marginal variance for formulation \(j\) is \(\sigma_j^2=\tau_b^2+\tau_{uj}^2+\sigma_{\epsilon j}^2\). Real replicate designs may have a more detailed covariance structure; planning must reproduce the actual design and its fitted analysis rather than substitute this illustration for the protocol model.

A Scenario-Based Robustness Assessment

A practical approach is to define a baseline planning model and then vary its assumptions one at a time and in coherent combinations. Parameter uncertainty means that the model form is retained but quantities such as residual or subject-by-formulation variances are changed. Model departure means changing the data-generating structure itself, such as introducing heavier tails, a different covariance pattern, or dependence between a random effect and another modeled quantity. These are related concerns, but they should not be conflated.

For each scenario, generate data under the planned design, apply the exact planned analysis, and record whether its prespecified population bioequivalence decision is positive. If \(M\) simulated studies are generated and \(K\) conclude bioequivalence, the estimated power is \(\hat{\pi}=K/M\). Its approximate Monte Carlo standard error is \(\sqrt{\hat{\pi}(1-\hat{\pi})/M}\). This describes simulation noise, not uncertainty in the underlying variance estimates or in the model assumptions.

1
Specify the planning target.
Set the target power, significance level, criterion, analysis method, design, and definition of sample size. State which assumptions are treated as baseline.
2
Define plausible alternatives.
Vary important variance components and mean differences over justified ranges. Add separate scenarios for plausible structural departures from the baseline random-effects model.
3
Estimate power in each scenario.
Simulate the planned study, fit the planned analysis, and apply the prespecified decision rule. Use enough replicates to make Monte Carlo error small relative to the planning decision.
4
Choose and report a robustness rule.
For example, require the minimum power across a stated plausible set to meet the target, or use a probability-weighted assurance if defensible probabilities over scenarios are available.

A minimum-power rule is conservative with respect to the scenarios included: it asks whether the target is achieved in the least favorable one. Assurance instead averages power over a distribution of uncertain parameters or scenarios. The two answer different questions. Neither protects against scenarios that were omitted, and assurance is only as defensible as the probability distribution used to weight them.

Worked Example: Sensitivity to Variance Components

Suppose a hypothetical balanced replicate study is planned with \(n=60\) evaluable subjects. The planned analysis uses the prespecified population bioequivalence rule, and the target power is 0.80. Investigators simulate \(M=20{,}000\) studies under three parameter settings, changing the variance components while keeping the design and mean assumptions fixed.

ScenarioSuccessful decisions \(K\)Estimated power \(\hat{\pi}=K/M\)
Baseline variance components16,6000.830
Lower plausible variance components17,2800.864
Higher plausible variance components15,6800.784

For the baseline, \(\hat{\pi}=16{,}600/20{,}000=0.830\). Its Monte Carlo standard error is approximately $$ \sqrt{\frac{0.830(1-0.830)}{20{,}000}}=0.00266. $$ For the higher-variance scenario, the estimated power is \(15{,}680/20{,}000=0.784\), with Monte Carlo standard error \(\sqrt{0.784(0.216)/20{,}000}=0.00291\). The baseline estimate exceeds the target, but the higher-variance scenario does not. The plan therefore does not meet an 0.80 minimum-power rule across these three scenarios. The shortfall is larger than the simulation noise, so simply increasing the number of simulated studies would not resolve it; the sample size or assumptions need reconsideration.

Uncertainty About Variance Inputs

Variance estimates used for planning are themselves uncertain. A single point estimate can give a misleadingly precise impression, especially when it comes from limited data or a design that estimates the components imprecisely. The earlier material on Evaluating Variance Estimates for Sample Size Planning and Sample Size Planning Under Uncertain Variance addresses the broader issue of uncertain inputs. In robust population bioequivalence planning, the key step is to connect that uncertainty to the particular components that determine \(\sigma_T^2\), \(\sigma_R^2\), and the variability of the planned estimator.

A sensitivity grid might vary each component over a justified range, while a joint parameter distribution can preserve dependence among component estimates. Varying one component at a time is useful for identifying drivers, but it can miss combinations that are plausible together. Conversely, combining the largest value of every component can create an implausible scenario. The choices should reflect the data and the study context, not a mechanical preference for extreme values.

Worked Example: Minimum Power Versus Assurance

Consider a hypothetical \(n=64\) design evaluated under three plausible variance scenarios. The scenario probabilities are assigned as \(0.25\), \(0.50\), and \(0.25\), respectively, based on a specified planning distribution. From \(20{,}000\) simulated studies per scenario, estimated powers are \(0.860\), \(0.800\), and \(0.700\).

The minimum power is $$ \min(0.860,0.800,0.700)=0.700. $$ Thus \(n=64\) does not meet a rule requiring power of at least 0.80 in every included scenario. The probability-weighted assurance is instead $$ 0.25(0.860)+0.50(0.800)+0.25(0.700) =0.215+0.400+0.175=0.790. $$ This is also below a target of 0.80, but it is close. A different sample size might meet the assurance target while still failing the minimum-power rule. The assurance calculation does not mean there is a 79% probability that the study will be successful; it is the average of scenario-specific powers under the stated scenario weights.

If the scenario probabilities are uncertain or merely subjective, report the assurance as conditional on those weights and show the scenario-specific powers as well. Reporting only an average can hide an important weak point. If the goal is a guarantee over a defined range, a minimum-power criterion is more directly aligned with that goal, although it may lead to a larger sample size.

Departures from the Planning Model

Parameter sensitivity alone does not test whether the assumed random-effects model is adequate. A normal random-effects model, for example, may be used to generate planning data, but the actual study could have heavier tails or a covariance pattern not represented by that model. Such departures may alter the sampling behavior of the variance estimates and the frequency with which the planned decision rule is satisfied. The consequence cannot be inferred from the direction of a single variance component alone; it depends on the estimator, design, and decision procedure.

Worked Example: A Heavier-Tailed Random Effect

Suppose a hypothetical baseline simulation for \(n=72\) subjects uses normally distributed subject-by-formulation effects and gives \(16{,}800\) positive decisions out of \(20{,}000\), or \(0.840\) estimated power. A second simulation keeps the same component variances and planned analysis but generates the subject-by-formulation effects from a standardized \(t\) distribution with 4 degrees of freedom, scaled to have variance 1. This scenario gives \(15{,}900\) positive decisions.

The heavier-tail estimate is \(15{,}900/20{,}000=0.795\). Its Monte Carlo standard error is $$ \sqrt{\frac{0.795(1-0.795)}{20{,}000}}=0.00285. $$ The change from \(0.840\) to \(0.795\) is much larger than either estimate's Monte Carlo error. Under this hypothetical model departure, the \(n=72\) plan falls just below a target of 0.80. This does not prove that the heavier-tailed model is the truth; it shows that the conclusion is sensitive to a plausible departure and should be reported as such.

Useful diagnostics include checking whether the assumed components are identifiable from the proposed design, whether simulated marginal variances and correlations match the intended values, and whether the analysis converges reliably across simulations. Inspect the distribution of estimated variance components and the frequency of boundary estimates, failed fits, or unusual decision outcomes. A simulation that silently discards failed fits can overstate power; the handling of failures must follow a prespecified rule and be reported.

A sensitivity analysis also has limitations. It cannot compensate for a poor estimand, incorrect implementation of the planned analysis, or unrepresentative scenarios. Simulations based on an incorrect covariance structure may be precise but answer the wrong question. Moreover, more simulation replicates reduce Monte Carlo error but do not reduce uncertainty about the true variance components. Those require better evidence, transparent ranges, or a justified distribution for the uncertain inputs.

Choosing and Communicating a Robust Plan

The most useful report gives the baseline assumptions, the range or distribution of uncertain components, the structural departures examined, and the resulting power at each candidate sample size. State whether selection is based on minimum power, assurance, or another explicit rule. If a target is missed only under a particularly adverse scenario, explain why that scenario is or is not considered plausible rather than hiding it in an average.

A common mistake is to calculate power using the most favorable variance estimate, obtain a value just above the target, and describe the sample size as adequately powered. The correction is to distinguish the baseline calculation from robustness: a baseline result supports a conclusion only under its stated assumptions. Evaluate plausible alternatives, account for Monte Carlo error, and qualify the recommendation according to the robustness rule actually used.

Compared with a single plug-in calculation, scenario analysis makes sensitivity visible but does not assign probabilities unless a distribution is specified. Compared with assurance, a minimum-power rule does not average over scenarios, but it directly identifies the weakest case in the chosen set. Neither approach replaces sound design or careful estimation; they are complementary ways to expose dependence on planning assumptions.

Key takeaway: A robust population bioequivalence plan is one whose power has been evaluated under explicit, plausible variance inputs and model departures. Report both the assumed scenario set and the rule used to select \(n\); a single favorable power estimate is not evidence of robustness.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions.

  1. In a simulation with \(M=10{,}000\) studies, 7,900 conclude bioequivalence. Calculate estimated power and its approximate Monte Carlo standard error.
  2. Three scenarios have powers 0.88, 0.82, and 0.68. Does this meet a target of 0.80 under a minimum-power rule? What is the unweighted average power?
  3. Why does increasing the number of simulation replicates not remove uncertainty in the true variance components?
  4. Give one example of parameter uncertainty and one example of a structural model departure.
  5. Why can a probability-weighted assurance conceal a planning weakness?

Solutions: (1) The estimated power is \(7{,}900/10{,}000=0.790\). The Monte Carlo standard error is \(\sqrt{0.790(0.210)/10{,}000}=0.00407\). (2) No: the minimum is \(0.68\), below 0.80. The unweighted average is \((0.88+0.82+0.68)/3=0.793\). (3) More replicates reduce simulation sampling error; they do not add information about the unknown components in the real population. (4) Changing a residual variance over a plausible range is parameter uncertainty; generating subject effects from a heavier-tailed distribution than the assumed normal model is a structural departure. (5) A high-power scenario can receive enough weight to raise the average even when a plausible scenario has substantially lower power; scenario-specific results should therefore accompany assurance.